Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) granted inducement awards on May 1, 2026, to eight new employees to purchase up to 162,100 shares under its 2023 Inducement Plan. The stock options vest over four years: 25% at one year, then 1/48th monthly over the following 36 months, subject to continued service.

AI-generated analysis. Not financial advice.

News Market Reaction – SNDX

-0.53%

1 alert

-0.53% News Effect

On the day this news was published, SNDX declined 0.53%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement option shares: 162,100 shares New employees: 8 Vesting period: 4 years +3 more

6 metrics

Inducement option shares 162,100 shares Options to purchase common stock granted May 1, 2026

New employees 8 Recipients of inducement awards under 2023 Inducement Plan

Vesting period 4 years Total vesting duration for inducement stock options

Cliff vesting 25% Portion vesting on one-year anniversary of vesting commencement

Monthly vesting fraction 1/48th Portion vesting monthly after first year

Post-cliff vesting period 36 months Monthly vesting duration following first-year cliff

Market Reality Check

Price: $21.49 Vol: Volume 1,579,212 is rough...

normal vol

$21.49 Last Close

Volume Volume 1,579,212 is roughly in line with 20-day average 1,645,007 (relative volume 0.96x). normal

Technical Price $20.10 is trading above the 200-day MA at $18.53 and about 21% below the 52-week high of $25.59.

Peers on Argus

SNDX is up 0.7% while key biotech peers like ARDX, BHVN, VERA, and VRDN show dec...

SNDX is up 0.7% while key biotech peers like ARDX, BHVN, VERA, and VRDN show declines between about 1.5% and 4.3%, suggesting stock-specific trading rather than a sector-wide move.

Historical Context

5 past events · Latest: Apr 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 30	Q1 2026 earnings	Positive	-10.8%	Strong Q1 2026 revenue growth but continuing net loss and high R&D and SG&A.
Apr 24	Earnings call date	Neutral	+1.9%	Announcement of Q1 2026 results date and investor conference call details.
Apr 03	Inducement grants	Neutral	-3.4%	Inducement stock options for up to 228,500 shares to eight new employees.
Mar 04	Inducement grants	Neutral	-0.2%	Inducement options for up to 81,600 shares for three new employees.
Feb 26	FY 2025 earnings	Positive	+5.0%	Q4 and FY25 revenue growth from Revuforj and Niktimvo with narrowed losses.

Pattern Detected

Earnings and business updates have produced sizable moves, with one notable negative divergence on a strong Q1 2026 print, while routine items like inducement grants have seen modest to small reactions.

Recent Company History

Over the last several months, Syndax has transitioned firmly into a commercial-stage profile, with strong revenue growth from Revuforj and Niktimvo highlighted in Q4 2025 and Q1 2026 earnings on Feb 26, 2026 and Apr 30, 2026. Those reports showed rapid top-line expansion but ongoing net losses and high R&D plus SG&A. Alongside this, Syndax has repeatedly issued inducement equity grants under its 2023 Inducement Plan, like the March and April 2026 awards, indicating continued hiring and equity-based compensation practices consistent with today’s announcement.

Market Pulse Summary

This announcement details routine inducement stock option grants for up to 162,100 shares to 8 new e...

Analysis

This announcement details routine inducement stock option grants for up to 162,100 shares to 8 new employees under Syndax’s 2023 Inducement Plan, vesting over four years with a one-year cliff and monthly vesting thereafter. It highlights continued use of equity compensation to attract and retain talent. In context of recent earnings showing strong revenue growth but ongoing losses, investors may monitor how cumulative equity awards evolve relative to hiring, expenses, and progress in late-stage programs.

Key Terms

inducement awards, nasdaq listing rule 5635(c)(4), stock options, vesting

4 terms

inducement awards financial

"the Company granted inducement awards to purchase up to 162,100 shares"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

nasdaq listing rule 5635(c)(4) regulatory

"Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

stock options financial

"The stock options will vest over four years, with 25% of the underlying shares"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vesting financial

"25% of the underlying shares vesting on the one-year anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. Not financial advice.

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026, the Company granted inducement awards to purchase up to 162,100 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre 
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

What inducement awards did Syndax (SNDX) grant on May 1, 2026?

The company granted inducement options to purchase up to 162,100 shares to eight new hires. According to the company, the awards were made under the 2023 Inducement Plan and are intended as new-hire equity compensation.

How do the SNDX inducement options vest and over what timeline?

Options vest over four years: 25% at one year, then 1/48th monthly over 36 months. According to the company, vesting is subject to each employee's continued service through the applicable vesting dates.

How many employees received inducement awards from Syndax (SNDX)?

Eight new employees received the inducement awards. According to the company, the grants were issued on May 1, 2026, under the company's 2023 Inducement Plan for new hires.

Will the SNDX inducement grants dilute existing shareholders?

The awards allow purchase of up to 162,100 shares, which could dilute existing holders if exercised. According to the company, actual dilution depends on future option exercises and outstanding shares at that time.

Where can investors find more details about Syndax (SNDX) inducement grants?

Investors can review company filings and investor materials for full terms and amounts. According to the company, the grants were made under the 2023 Inducement Plan and are described in its disclosures dated May 6, 2026.